Valeria Gasperi
Overview
Explore the profile of Valeria Gasperi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gambacurta A, Tullio V, Savini I, Mauriello A, Catani M, Gasperi V
Int J Mol Sci
. 2025 Jan;
26(1.
PMID: 39796183
MicroRNA (miR)-126 is frequently downregulated in malignancies, including breast cancer (BC). Despite its tumor-suppressive role, the mechanisms underlying miR-126 deregulation in BC remain elusive. Through silencing experiments, we identified Early...
2.
Gambacurta A, Tullio V, Savini I, Catani M, Gasperi V
Methods Mol Biol
. 2024 Sep;
2834:293-301.
PMID: 39312171
The development of novel drug candidates is a current challenge in pharmacology where therapeutic benefits must exceed side effects. Toxicology testing is therefore a fundamental step in drug discovery research....
3.
Azzini E, Furini T, Polito A, Scalfi L, Pinto A, Gasperi V, et al.
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38732007
Due to the high mortality rate in Western countries, pancreatic cancer is considered one of the , leaving patients and their families with little hope upon diagnosis. Although surgical and...
4.
Piro M, Gasperi V, De Stefano A, Anemona L, Cenciarelli C, Montanaro M, et al.
Int J Mol Sci
. 2023 Aug;
24(15).
PMID: 37569534
The highly dynamic nature of chromatin's structure, due to the epigenetic alterations of histones and DNA, controls cellular plasticity and allows the rewiring of the epigenetic landscape required for either...
5.
Gambacorta N, Gasperi V, Guzzo T, Di Leva F, Ciriaco F, Sanchez C, et al.
Eur J Med Chem
. 2023 Jul;
259:115647.
PMID: 37478557
The discovery of selective agonists of cannabinoid receptor 2 (CB) is strongly pursued to successfully tuning endocannabinoid signaling for therapeutic purposes. However, the design of selective CB agonists is still...
6.
Catani M, Tullio V, Maccarrone M, Gasperi V
Methods Mol Biol
. 2022 Sep;
2576:133-143.
PMID: 36152182
Dysregulation of peroxisome proliferator-activated receptor (PPAR)-γ has been described in a plethora of pathological conditions, such as diabetes, obesity, inflammatory-related diseases, and cancer. Therefore, identifying novel drugs that are able...
7.
Gasperi V, Savini I, Catani M
Methods Mol Biol
. 2022 Sep;
2576:95-109.
PMID: 36152179
Type-1 cannabinoid receptor (CB), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both the central nervous system and peripheral tissues. Today,...
8.
Gasperi V, Guzzo T, Topai A, Gambacorta N, Ciriaco F, Nicolotti O, et al.
Curr Med Chem
. 2022 Aug;
30(12):1420-1457.
PMID: 36028971
In the last decade, selective modulators of type-2 cannabinoid receptor (CB) have become a major focus to target endocannabinoid signaling in humans. Indeed, heterogeneously expressed within our body, CB actively...
9.
Catani M, Savini I, Gasperi V
Int J Mol Sci
. 2022 May;
23(10).
PMID: 35628340
Zhao and Devine [...].
10.
Sibilano M, Tullio V, Adorno G, Savini I, Gasperi V, Catani M
Int J Mol Sci
. 2022 May;
23(10).
PMID: 35628294
Among the surrounding cells influencing tumor biology, platelets are recognized as novel players as they release microvesicles (MVs) that, once delivered to cancer cells, modulate signaling pathways related to cell...